Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 5/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.67 |
| ▸ | MTOR | P42345 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Colterol SCHEMBL3220142 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL249585 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL10604477 | 0.92 | ADRB2 (0.63) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL636005 | 0.92 | PMP22 (0.71) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL6711726 | 0.87 | ADRB2 (0.68) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL30438779 | 0.87 | ADRB2 (0.68) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Terbutaline SCHEMBL1668880 | 0.86 | ADRB2 (0.67) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL20819658 | 0.85 | ADRB1 (0.69) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL20833681 | 0.85 | ADRB1 (0.69) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL11278982 | 0.85 | ADRB2 (0.62) | ADRB2ADRB1TSHRHIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116801875-A | Compositions and methods for ameliorating neurological diseases and disorders | 库拉森疗法公司 | 2023-09-22 | — | — | CN | claimed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | claimed |
| WO-2025059259-A1 | NEW PROCESS FOR PHENYLEPHRINE AND SALBUTAMOL AND RELATED COMPOUNDS VIA ASYMETRIC TRANSFER HYDROGENATION OF UNPROTECTED AMINO KETONES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-2117524-B1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | ADRB2 4/4885ADRB1 2/4885TSHR 920/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | ADRB2 7/4885ADRB1 4/4885TSHR 2951/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | ADRB2 1/4885ADRB1 2/4885TSHR 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.